1 - 4 August 2024

PERTH CONVENTION AND EXHIBITION CENTRE

Sponsored Symposia

Friday 4 August, 0715 - 0815


Amgen.jpg

Strike early and strike strong: LDL-C reduction in very high-risk ASCVD patients.

 


AZ.jpg

How better understanding HFpEF can help in identifying and treating HFpEF


CSL Seqrius.jpg

Consensus statement for hypertriglyceridemia management: Implementation guide for MACE prevention with a special focus on use of Icosapent Ethyl in the Australia.


GSK.jpg

 

 

Potential risk and impact of viral infections in patients with cardiovascular disease.


Novartis.jpg
Breaking Barriers in HFrEF Care: Implementing New Models for Improved Outcomes


Novo.jpg

Why Weight? Managing obesity in CVD: how, when and why?

Speakers: Prof Pam Taub and A/Prof Melissa Leung

Chair: Prof Gerald Watts

Synopsis: Obesity can lead to the development of CVD and CVD mortality independently of other cardiovascular risk factors. Hear from a panel of local and international experts including Prof Pam Taub Cardiologist and Professor of Medicine at UC San Diego, alongside A/Prof Melissa Leung & Prof Gerald Watts as they discuss patient cases and share their clinical experience and practical tips on optimising the use of GLP-1RAs in managing overweight or obesity in patients with CVD. 


Pfizer.jpg

VYNDAMAX and ATTR-CM: What Cardiologists need to know.

 

Friday 4 August, 1235 - 1335


bms_logo_rgb_pos_300.jpg


Cardiac myosin inhibition in HCM: Translating theory to practice

 


GSK.jpg

 

 

 

 

 

 

What is your role in preventing the impact of viral infection through vaccination?


Novartis.jpg

Unlocking the Potential of Leqvio (inclisiran): A Masterclass with Prof Kausik Ray and Prof Stephen Nicholls

Speakers: Prof Kausik Ray, Prof Stephen Nicholls